Abilify: Restoring Balance in Mental Health Treatment
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.90 | $54.17 (0%) | 🛒 Add to cart |
| 90 | $0.78 | $81.25 $70.22 (14%) | 🛒 Add to cart |
| 180 | $0.66 | $162.51 $118.37 (27%) | 🛒 Add to cart |
| 270 | $0.62 | $243.76 $166.52 (32%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $325.01 $214.67 (34%) | 🛒 Add to cart |
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.54 | $46.14 (0%) | 🛒 Add to cart |
| 60 | $1.09 | $92.29 $65.20 (29%) | 🛒 Add to cart |
| 90 | $0.94 | $138.43 $84.26 (39%) | 🛒 Add to cart |
| 120 | $0.85 | $184.58 $102.32 (45%) | 🛒 Add to cart |
| 180 | $0.79 | $276.86 $141.44 (49%) | 🛒 Add to cart |
| 270 | $0.74 | $415.30 $198.62 (52%) | 🛒 Add to cart |
| 360 | $0.70
Best per pill | $553.73 $253.79 (54%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.47 | $74.23 (0%) | 🛒 Add to cart |
| 60 | $1.76 | $148.46 $105.33 (29%) | 🛒 Add to cart |
| 90 | $1.52 | $222.70 $136.43 (39%) | 🛒 Add to cart |
| 120 | $1.39 | $296.93 $166.52 (44%) | 🛒 Add to cart |
| 180 | $1.27 | $445.39 $228.71 (49%) | 🛒 Add to cart |
| 270 | $1.19 | $668.09 $322.01 (52%) | 🛒 Add to cart |
| 360 | $1.15
Best per pill | $890.78 $414.29 (53%) | 🛒 Add to cart |
Synonyms | |||
Abilify (aripiprazole) is an atypical antipsychotic medication designed to provide effective management for a range of psychiatric conditions. It functions as a dopamine partial agonist, offering a unique mechanism of action that helps stabilize dopamine and serotonin activity in the brain. This profile provides a comprehensive, expert-level overview of its clinical use, ensuring healthcare professionals and informed patients have access to detailed, evidence-based information. Proper understanding of its pharmacology, administration, and safety profile is essential for optimizing therapeutic outcomes and minimizing risks.
Features
- Active ingredient: Aripiprazole
- Available formulations: Oral tablets, orally disintegrating tablets, oral solution, and injectable formulations
- Mechanism of action: Dopamine D2 and serotonin 5-HT1A partial agonist; serotonin 5-HT2A antagonist
- Half-life: Approximately 75 hours (aripiprazole) and 94 hours (major active metabolite, dehydro-aripiprazole)
- FDA-approved for: Schizophrenia, bipolar I disorder (manic/mixed episodes, maintenance), adjunctive treatment of major depressive disorder, irritability associated with autistic disorder, and Tourette’s disorder
Benefits
- Effectively reduces positive and negative symptoms in schizophrenia
- Helps stabilize mood in bipolar disorder, preventing manic and depressive episodes
- Provides adjunctive efficacy in major depressive disorder when response to antidepressants is inadequate
- Offers multiple administration routes for flexibility in treatment across different clinical scenarios
- Generally exhibits a favorable metabolic side effect profile compared to some other antipsychotics
- May improve overall functioning and quality of life in chronic mental health conditions
Common use
Abilify is commonly prescribed for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is also widely used in the management of acute manic and mixed episodes associated with bipolar I disorder in adults and pediatric patients aged 10 years and older, as well as for maintenance monotherapy in bipolar I disorder. Additionally, it is indicated as an adjunctive therapy to antidepressants for major depressive disorder in adults. Other approved uses include the treatment of irritability associated with autistic disorder in pediatric patients aged 6 to 17 years, and for Tourette’s disorder in pediatric patients aged 6 to 18 years. Off-label uses may include other psychiatric conditions, but these should be carefully evaluated by a healthcare provider.
Dosage and direction
Dosage must be individualized based on the clinical condition, patient response, and tolerability. For schizophrenia in adults, the recommended starting dose is 10–15 mg once daily, with a target range of 10–30 mg daily. For bipolar mania, the initial dose is 15 mg once daily, which may be increased to 30 mg daily if necessary. As adjunctive treatment for major depressive disorder, the starting dose is 2–5 mg daily, with adjustments in 5 mg increments up to a maximum of 15 mg daily. For pediatric populations, dosing is weight-based and should follow specific guidelines. Abilify can be taken with or without food. The oral solution should be measured using the calibrated device provided. Long-acting injectable formulations (e.g., Abilify Maintena) are administered monthly by healthcare professionals.
Precautions
Patients should be monitored for the emergence of suicidal thoughts and behaviors, particularly at the beginning of treatment or during dosage adjustments. There is an increased risk of cerebrovascular adverse events, including stroke, in elderly patients with dementia-related psychosis. Neuroleptic malignant syndrome (NMS), a rare but potentially fatal reaction, may occur and requires immediate discontinuation and medical intervention. Tardive dyskinesia, a syndrome of potentially irreversible involuntary movements, may develop with long-term use. Abilify may impair judgment, thinking, or motor skills; patients should be cautioned about operating machinery or driving until they know how the medication affects them. Regular monitoring of weight, blood glucose, and lipid levels is recommended due to potential metabolic changes.
Contraindications
Abilify is contraindicated in patients with a known hypersensitivity to aripiprazole or any component of the formulation. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) may require dosage adjustments and is relatively contraindicated without careful supervision. Use in patients with severe hepatic impairment requires caution and potential dosage reduction. It is not approved for use in patients with dementia-related psychosis due to increased mortality risk.
Possible side effect
Common side effects may include akathisia, headache, anxiety, insomnia, nausea, vomiting, lightheadedness, drowsiness, and constipation. Less frequently, weight gain, blurred vision, increased salivation, and orthostatic hypotension may occur. Serious side effects can include neuroleptic malignant syndrome, tardive dyskinesia, hyperglycemia and diabetes mellitus, dyslipidemia, seizures, dysphagia, and leukopenia, neutropenia, or agranulocytosis. Any unusual or severe side effects should be reported to a healthcare provider immediately.
Drug interaction
Abilify is primarily metabolized by CYP3A4 and CYP2D6 enzymes. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) or strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, quinidine) may increase aripiprazole concentrations and necessitate dose reduction. Conversely, strong CYP3A4 inducers (e.g., carbamazepine, rifampin) may decrease aripiprazole levels and require dose adjustment. Caution is advised when combining with other central nervous system depressants (e.g., alcohol, benzodiazepines, opioids) due to additive sedative effects. Abilify may enhance the hypotensive effects of antihypertensive medications.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is close to the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling up on doses is not recommended. For patients on the long-acting injectable formulation, contact the healthcare provider to reschedule the injection as soon as possible.
Overdose
In cases of overdose, supportive measures should be instituted, and close medical supervision is required. Symptoms may include drowsiness, vomiting, agitation, aggression, confusion, tremors, seizures, coma, or potentially fatal outcomes due to respiratory depression or cardiovascular collapse. There is no specific antidote for aripiprazole overdose; management focuses on symptomatic treatment and sustaining vital functions. Gastric lavage or administration of activated charcoal may be considered if ingestion was recent. Immediate medical attention is essential.
Storage
Store Abilify tablets, orally disintegrating tablets, and oral solution at room temperature (15–30°C or 59–86°F). Protect from light and moisture. Keep the oral solution in the original bottle and do not freeze. The calibrated dosing device should be rinsed after each use. Keep all medications out of reach of children and pets. Do not use beyond the expiration date printed on the packaging.
Disclaimer
This information is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read in this document. Individual patient responses to medication may vary.
Reviews
Clinical trials and post-marketing surveillance have generally reported favorable efficacy and tolerability for Abilify in its indicated uses. Many patients and clinicians note improvements in symptom control and functional outcomes, particularly appreciating its partial agonist mechanism which may result in a lower incidence of certain side effects like weight gain and sedation compared to other antipsychotics. However, experiences with side effects such as akathisia can vary. Long-term user reviews often emphasize the importance of regular follow-up and dosage individualization. Overall, it remains a widely used and respected option in psychiatric pharmacotherapy.